

References

1. **Agostini M, Silva SD, Zecchin KG, Coletta RD, Jorge J, Loda M, Graner E. (2004):** Fatty acid synthase is required for proliferation of human oral squamous carcinoma cells. *Oral Oncol.*; 40(7): 728-35.
2. **Amling CL, (2001):** Diagnosis and management of superficial bladder cancer. *Curr. Probl. Cancer*; 25: 219-78.
3. **Anwar K, Phill M, Naiki K, Nakakuki K, Inuzuka M (1992):** High frequency of human papilloma virus infection in carcinoma of the urinary bladder. *Cancer (Phila.)* 70 :1967–73.
4. **Ashkenazi A, Dixit VM (1998):** Death receptors: Signaling and modulation. *Science*;281:1305–1308.
5. **Banner D, D'Arcy A, Janes W, Gentz R, Schoenfeld H, Broger C, Loetscher H, Lesslauer W, (1993):** Crystal structure of the soluble human 55kd TNF receptor-human TNF β complex: implications for TNF receptor activation. *Cell*; 73: 431-45.
6. **Bartek J, Lukas J, Bartkova J, (1999):** Perspective: Defects in cell cycle control and cancer. *J Pathol*; 187:95–9.
7. **Beg AA, Baltimore D, (1996):** An essential role for NF-kappaB in preventing TNF-alpha induced cell death. *Science*; 274: 782-4.
8. **Behrman AJ, Salomone JA, Taylor JP, Halamka J (2004):** Schistosomiasis; eMedicine.com, Inc.
9. **Boucher NR, Scholefield JH, Anderson JB (1996):** The etiological significance of human papilloma virus in bladder cancer. *Br J Urol*; 78 6: 866–9.
10. **Buchumensky V, Klein A, Zemer R, Kessler O, Zimlichman S and Nissenkorn I, (1998):** Cytokeratin 20: A new marker for early detection of bladder cell carcinoma. *J Urology*; 160: 1971–4.
11. **Butterworth AE (1998):** Immunological aspects of human schistosomiasis. *Br Med Bulletin*; 54(2): 357-68.
12. **Bodmer JL, Burns K, Schneider P, Hofmann K, Steiner V, Thome M, Bornand T, French L, Tschopp J, (1997):** TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas (Apo-1/CD95). *Immunity*; 6: 79-88.
13. **Bolding MP, Goncharov TM, Goltsev YV, Wallach D (1996):** Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/Apo-1- and TNF receptor-induced cell death. *Cell*; 85: 803-15.

14. **Brunner T, (2000):** Expression of Fas ligand in activated T cells is regulated by c-Myc. *J Biol Chem*; 275: 9767-72.
15. **Bunz F, Dutriaux A, Lengauer C, (1998):** Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science*; 282: 1497–501.
16. **Cairns P, Proctor AJ, Knowes MA (1991):** Loss of heterozygosity at the Rb locus is frequent and correlates with muscle invasion in bladder cancer. *Oncogene*;6:2305.
17. **Cairns P, Tokino K, Eby Y, Sidransky D (1994):** Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. *Cancer Res*; 54:1422.
18. **Cairns JP, Chang PW, Ramamoothy S (1998):** A comparison between microsatellite and quantitative PCR analyses to detect frequent p16 copy number changes in primary bladder tumors. *Clin Cancer Res*;4: 441.
19. **Cascino I, Fiucci G, Papoff G, Ruberti G, (1995):** Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. *J Immunol*; 154: 2706-13.
20. **Cascino I, Papoff G, De Maria R, Testi R, Ruberti G, (1996):** Fas/Apo-1/CD95 receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. *J Immunol* 156, 13-7.
21. **Chan, H., Bartos, D.P. and Owen-Schaub, L.B. (1999):** Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. *Mol Cell Biol*; 19: 2098-108.
22. **Cheng L, Bostwick DG (2000):** World Health Organization and International Society of Urological Pathology classification and two-number grading system of bladder tumors. *Reply. Cancer*;88:1513.
23. **Cheng J, Zhou T, Liu C, Shapiro J, Brauer M, Kiefer M, Barr J, Mountz J, (1994):** Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. *Science*; 263: 1759-62.
24. **Cheng J, Liu C, Koopman W, Mountz, J. (1995):** Characterization of the human Fas gene. Exon/Intron organization and promoter region. *J Immunol*; 154: 1239-45.
25. **Cheng L, Darson M, Cheville JC (1999):** Urothelial papilloma of the bladder. *Cancer*;86:208.
26. **Cheng L, Cheville JC, Neumann RM, Bostwick DG (2000):** Flat intraepithelial lesions of the urinary bladder. *Cancer*;88:625.
27. **Chernovsky AV, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA & Matis LA (1997):** The role of Fas in autoimmune diabetes. *Cell*; 89: 17-24.

28. **Chinnaiyan A, O'Rourke K, Yu G, Lyons R, Garg M, Dixit VM, (1996):** Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. *Science*; 274: 990-2.
29. **Chopin D, Barei-Moniri R, Maillé P, Le Frère-Belda M, Muscatelli-Groux B, Merendino N, Lecerf L, Stoppacciaro A, Velotti F (2003):** Human Urinary Bladder Transitional Cell Carcinomas Acquire the Functional Fas Ligand during Tumor Progression. *Am J Path.*; 162: 1139-49
30. **Chow, W.A., Fang, J.J. and Yee, J.K. (2000):** The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. *J Immunol*; 164: 3512-8.
31. **Cifone MG, (1994):** Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. *J Exp Med*; 180: 1547-52.
32. **Clurman BE, Porter P (1998):** New insights into the tumor suppression function of P27(kip1). *Proc Natl Acad Sci USA*; 95: 15158–60.
33. **Cordon-Cardo C, Wartinger D, Petrylak D, (1992):** Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. *J Natl Cancer Inst*; 84: 1251–6.
34. **Costello AJ, Tiptaft RC, England HR (1984):** Squamous cell carcinoma of the bladder. *Urology*; 23: 234.
35. **Cote RJ, Chatterjee SJ (1999):** Molecular determinants of outcome in bladder cancer. *Cancer J Sci Am.*; 5: 1.
36. **Czerniak B, Herz F (1995):** Molecular biology of common tumors of the urinary tract. In: Koss LG (ed): *Diagnostic Cytology of the Urinary Tract*. Philadelphia, Lippincott-Raven; Pp: 345–64.
37. **Deveraux QL, (1998):** IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. *Embo J*; 17: 2215-23.
38. **Diehl JA, Cheng M, Roussel MF, Sherr CJ, (1998):** Glycogen synthase kinase-3 β regulates cyclin D1 proteolysis and subcellular localization. *Genes Dev*; 12: 3499–511.
39. **Dynlacht BD, Flores O, Lees JA, Harlow E (1994):** Differential regulation of E2F transactivation by cyclin/cdk2 complexes. *Genes Dev*; 8: 1772–86.
40. **Edwards PD, Hurm RA, Jaeschke WH (1972):** Conversion of cystitis glandularis to adenocarcinoma. *J Urol*; 108: 56.
41. **Eidsomo L, Wolday D, Berhe N, Sabri F, Satti I, El Hassan AM, Sundar S, Chiodi F, Akuffo H (2002):** Alteration of Fas and Fas ligand expression during human visceral leishmaniasis. *Clin Exp Immunol.*; 130(2): 307-13.

42. **El-Bolkainy MN, Mokhtar NM, Ghoneim MA (1981):** The impact of schistosomiasis on the pathology of bladder carcinoma. *Cancer*; 48: 2643.
43. **Elledge SJ, (1996):** Cell cycle checkpoints: Preventing an identity crisis. *Science*; 274:1664–72.
44. **Elliott DE (1996):** Schistosomiasis. Pathophysiology, diagnosis, and treatment. *Gastroenterol Clin North Am.*; 25(3): 599-625.
45. **Enari M, Talanian R, Wong W, Nagata S, (1996):** Sequential activation of ice-like and CPP32-like proteases during fas-mediated apoptosis. *Nature*; 380: 723-6.
46. **Engel P, Anagnostaki L, Braendstrup O (1992):** The muscularis mucosa of the human urinary bladder. Implications for tumor staging on biopsies. *Scand J Urol Nephrol*; 26: 249.
47. **Epstein JI, Amin MB, Reuter VR, Mostofi FK:** The Bladder Consensus Conference Committee. The World Health Organization/International Society of Urologic Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. *Am J Surg Pathol*; 22: 1435.
48. **Esrig D, Elmajian D, Groshen S (1994):** Accumulation of nuclear p53 and tumor progression in bladder cancer. *New Engl J Med*; 331: 1259.
49. **Evan GI, Littlewood T (1998):** A matter of life and cell death. *Science*; 281: 1317-22.
50. **Farrow GM, Utz DC, Rife CC (1976):** Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy. *Cancer Res*; 36: 2495.
51. **Faysal MH, Freiha FS (1981):** Primary neoplasm in vesical diverticula. *Br J Urol*; 53:141.
52. **Fisher RA (1964):** Statistical methods for research workers, 10th ed., Deliver and Boyed, Edinburgh.
53. **Friend SH, Bernards R, Rogelj S, (1986):** A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature*; 323: 643–6.
54. **Furuya Y, Fuse H, Masai M. (2001):** Serum soluble Fas level for detection and staging of prostate cancer. *Anticancer Res.*; 21(5): 3595-8.
55. **Gad El-Mawla N, Hamza MR, Zekri KZ (1989):** Chemotherapy in invasive carcinoma of the bladder: a review of phase II trials in Egypt. *Acta Oncol*; 28: 73–6.
56. **Giaccia AJ, Kastan MB (1998):** The complexity of p53 modulation: Emerging patterns from divergent signals. *Genes Dev*; 12: 2973–83.

57. **Gibler WB, Diop D (1998):** Parasitology. In: Emergency Medicine: Concepts and Clinical Practice, Rosen S, (ed), Mosby-Year Book; Ch 3: 59-68.
58. **Ghoneim M, El-Mekresk M, El-Baz M, El-Attar I and Ashamallah A (1997):** Radical cystectomy for carcinoma of the bladder, critical evaluation of the results in 1026 cases. J Urol; 158: 393–9.
59. **Glashan RW, (1987):** Assessment and treatment of superficial bladder tumors. Recent Advances in Urology; 4:187-203.
60. **Griffith TS, Ferguson TA (1997):** The role of FasL-induced apoptosis in immune privilege. Immunol Today; 18: 240-4.
61. **Grossman HB & Dinney CP (2000):** Markers of bladder cancer State of the art. Urol. Oncol.; 5(1): 3-10.
62. **Habuchi T, Takahashi R, Yamada H (1994):** Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancers. Cancer Res; 53: 3794–5.
63. **Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991):** p53 mutations in human cancers. Science; 253: 49–53.
64. **Horowitz JM, Park SH, Bogenmann E (1990):** Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA; 87: 2775–9.
65. **Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW, (1996):** NMR structure and mutagenesis of the Fas (Apo-1/CD95) death domain. Nature; 384: 638-41.
66. **Huang, D.C., Cory, S. and Strasser, A., (1997):** Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene; 14: 405-14.
67. **Hughes D, Crispe I, (1995):** A Naturally occurring soluble isoforms of murine Fas generated by alternative splicing. J Exp Med; 182: 1395-1401.
68. **Hsu HL, Shu HB, Pan MG, Goeddel DV (1996):** TRADD-TRAF2 and tradd-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell; 84: 299-308.
69. **Hsu SC (1999):** NF-kappa B-dependent Fas ligand expression. Eur J Immunol; 29: 2948-56.
70. **Irmeler M (1997):** Inhibition of death receptor signals by cellular FLIP. Nature; 388: 190-5.
71. **Irmeler M, Thome M, Hahne M (1997):** Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190–195.
72. **Itoh N, Nagata S (1993):** A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J Biol Chem; 268: 10932-7.

73. **Itoh N, Tsujimoto Y, Nagata S (1993):** Effect of bcl-2 on Fas antigen-mediated cell death. *J Immunol*; 151: 621-7.
74. **Jaffrezou JP, Levade T, Bettaieb A, Laurent G (1996):** Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. *EMBO J*; 15: 2417-24.
75. **Joashi T, Fujiwara T, Tanida A, Hizuta M (2002):** Serum FasL during cardiopulmonary bypass; *J Cardiosurg*; 26: 325-9.
76. **Jodo S, Tanaka M, Cheng J (1998):** An assay for sFas and sFasL in plasma. *Clin. Exp. Immunol.*; 112:166.
77. **Jorulf H, Lindstedt C (1985):** Urogenital schistosomiasis : CT evaluation. *Radiology*; 157: 745-9.
78. **Juo P, Kuo C, Reynolds S, Konz R, Raingeaud J, Davis R, Biemann H, Blenis J, (1997):** Fas activation of the p38 mitogen-activated protein kinase signaling pathway requires ICE/CED-3 family proteases. *Mol Cell Biol*; 17: 24-35.
79. **Kastan MB, Zhan Q, El-Deiry WS, (1992):** A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. *Cell*; 71: 587–97.
80. **Kawahito K, Misawa Y, Fuse K. (2000):** Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery. *Artif Organs*; 24(8): 628-31.
81. **Khaled HM, Gad El-Mawla N, El-Saeid A, Hamza MP, Magrath I (1996):** Combination chemotherapy for advanced bilharzial bladder cancer. *Ann Oncol*; 7: 7512–4.
82. **Khaled HM, Bahnassi AA, Zekri AN, Aboul Kassem H, Mokhtar N (2003):** Correlation between p53 mutations and HPV in bilharzial bladder cancer. *Urol Oncol Semin Original Invest*; 21(5): 334-41.
83. **King ED, Matteson J, Jacobs SC, Kyprianou N (1996):** Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: Association with tumor progression. *J Urol*; 155: 316–20.
84. **Knipping E, Debatin K, Stricker K, Heilig B, Eder A, Krammer P, (1995):** Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. *Blood*; 85: 1562-9.
85. **Knowles MA, Williamson M (1993):** Mutation of H-ras is infrequent in bladder cancer: Confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. *Cancer Res*; 53: 133.

86. **Knowles MA, Elder PA, Williamson M (1994):** Allelotype of human bladder cancer. *Cancer Res* 1994;54:531.
87. **Koss LG, Esperanza MT, Robbins MA (1974):** Mapping cancerous and precancerous bladder changes: A study of the urothelium in ten surgically removed bladders. *JAMA*; 227: 281.
88. **Kroemer G, (1997):** The proto-oncogene Bcl-2 and its role in regulating apoptosis. *Nat Med*; 3: 614-20.
89. **Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH (1992):** Laimins, Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. *EMBO J*; 11: 3045–52.
90. **Levine AJ, (1997):** p53, the cellular gatekeeper for growth and division. *Cell*; 88: 323–31.
91. **Li XR (1999):** Transcriptional regulation of Fas gene expression by GA-binding protein and AP-1 in T cell antigen receptor.CD3 complex-stimulated T cells. *J Biol Chem*; 274: 35203-10.
92. **Li F, Ambrosini G, Chu EY (1998):** Control of apoptosis and mitotic spindle checkpoint by survivin. *Nature*;396: 580–4.
93. **Li H, Yu L, Guo Y, Ding Y, Liu L (2000):** Expression of Fas ligand in urogenital malignant cell lines and renal cell carcinoma. *Zhonghua Wai Ke Za Zhi.*; 38(3):201-3 [English Abstract].
94. **Lipponen P, Aaltomaa S (1994):** Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. *J Pathol*; 173: 333–9.
95. **Logothetis CJ, Xu HJ, Ro JY, (1992):** Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. *J Natl Cancer Inst*; 84: 1256–61.
96. **Lui C, Cheng J, Mountz D, (1995):** Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. *Biochem J*; 310: 957-63.
97. **Lundy SK, Lerman SP, Boros DL (2001):** Soluble egg antigen-stimulated T helper lymphocyte apoptosis and evidence for cell death mediated by FasL(+) T and B cells during murine *Schistosoma mansoni* infection. *Infect Immun.*; 69(1): 271-80.
98. **Lynch CF, Cohen MB (1995):** Urinary system. *Cancer*; 75(suppl):316.
99. **Lynch DH, Ramsdell F, Alderson MR, (1995):** Fas and FasL in the homeostatic regulation of immune responses. *Immunol Today*; 16: 569-74.
100. **Mariani SM, Matiba B, Armandola EA, Krammer PH (1997):** Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. *J Cell Biol*; 137: 221–9.

101. **Martin S, Green D, (1995):** Protease activation during apoptosis: death by a thousand cuts? *Cell*; 82: 349-52.
102. **Maas S, Warskulat U, Steinhoff C, Mueller W, Grimm MO, Schulz WA, Seifert HH. (2004):** Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. *Urology*; 63(2): 392-7.
103. **Mao L, Lee DJ, Tockman MS (1994):** Microsatellite alterations as clonal markers for the detection of human cancer. *Proc Natl Acad Sci U S A*; 91: 9871.
104. **May P, May E (1999):** Twenty years of p53 research: Structural and functional aspects of the p53 protein. *Oncogene* 1999;18:7621–7636.
105. **McGill G, Fischer D, (1997):** Apoptosis in tumorigenesis and cancer therapy. *Frontiers in Bioscience*, PubMed, Home J Library Index, Caveat Lector.
106. **Medema JP, (1997):** FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). *Embo J*; 16: 2794-804.
107. **Merchant SA, Amonkar PP (2002):** Genitourinary Bilharziasis: A Review. *Ind J Radiol Imag.*; 2: 239-44.
108. **Messing EM (2002):** Urothelial Tumors of the Urinary Tract. In: Campbell's Urology, Walsh PC, Retik AB, Vaughan AD, Vain AG, (eds), 8th ed., Saunders, Philadelphia, Vol. 4, 10: 76
109. **Midis PA, Humphrey PE, Swanson MR, Wick MA (1996):** Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of Fas, p53, Epidermal Growth Factor Receptor, and bcl-2. *Cancer*; 80: 715–23.
110. **Mizutani Y, Yoshida O, Bonavida B. (1998):** Prognostic significance of soluble Fas in the serum of patients with bladder cancer. *J Urol.*; 160(2):571-6.
111. **Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T, (2001):** Significance of serum soluble Fas ligand in patients with bladder carcinoma. *Cancer*; 92: 287-93.
112. **Mizutani Y, Yoshida O, Ukimura O, Kawauchi A, Bonavida B, Miki T. (2002):** Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. *Cancer Biother Radiopharm*; 17(5): 563-7.
113. **Mokhtar N (1991):** Cancer pathology Registry 1985–1989, National Cancer Institute, Cairo University, Department of Pathology, Natl. Cancer Inst. Al-Asdkaa G. C. Cairo: 12–9.

114. **Momand J, Zambetti GP, Olson DC, (1992):** The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. *Cell*; 69: 1237–45.
115. **Munsch, D., (2000):** Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. *J Biol Chem*; 275: 3867-72.
116. **Murakami m, Strobel M, Wounde G (1995):** Cell cycle regulation, oncogens and antineoplastic drugs. In: *Molecular Basis of Cancer*, Mendelson J, Howley P, Israel M, Liotta L (eds), Saunders, Philadelphia; Pp: 3-17.
117. **Murphy WM, Soloway MS (1982):** Urothelial dysplasia. *J Urol*;127:849.
118. **Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., Orourke, K., Shevchenko, A., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Peter, M.E., and Dixit, V.M., (1998):** Flice, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) death-inducing signaling complex. *Cell*; 85: 817-27.
119. **Nagata S, (1997):** Apoptosis by death factor. *Cell*; 88: 355-65.
120. **Nagata S, (1999):** Fas ligand-induced apoptosis. *Ann Rev Genet*; 33: 29-55.
121. **Nagata S, Golstein P, (1995):** The Fas death factor. *Science*; 267: 1449-56.
122. **Nagata S, Suda T (1995):** Fas and Fas ligand: *lpr* and *gld* mutations. *Immun Today*; 16: 39
123. **Natoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, Balsano, C, Levrero M, (1995):** Resistance to Fas-mediated apoptosis in human hepatoma cells. *Oncogene*; 11: 1157-64.
124. **Nonomura N, Nishimura K, Ono Y, Fukui T, Harada Y, Takaha N, Takahara S, Okuyama A (2000):** Soluble Fas in serum from patients with renal cell carcinoma. *Urology.*; 55(1): 151-5.
125. **Nurse P (1997):** Checkpoint pathways come of age. *Cell*; 91: 865–7.
126. **O’Connell J (2001):** Role of Fas–FasL in inflammatory diseases. *Exp Rev Mol*; <http://www-ermm.cbcu.cam.ac.uk/01003969h.htm>
127. **Owen-Schaub L, Radinsky R, Kruzel L, Berry K, Yonehara K, (1994):** Anti-Fas mediated apoptosis in nonhematopoietic tumors: neither Fas/Apo-1 nor bcl-2 expression is predictive of biological responsiveness. *Cancer Res* 54, 1580-6.
128. **Owen-Schaub L, Angelo L, Radinsky R, Ware C, Gesner T, Bartos, D (1995):** Soluble Fas/Apo-1 in tumor cells: a potential regulator of apoptosis. *Cancer Letters*; 94: 1-8.

129. **Pan G, Ni J, Wei YF (1997a)**: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science*; 277: 815–8.
130. **Pan G, O'Rourke K, Chinnaiyan AM (1997b)**: The receptor for the cytotoxic ligand TRAIL. *Science*; 276: 111–3.
131. **Pardee AB (1989)**: G1 events and regulation of cell proliferation. *Science*; 246: 603–8.
132. **Pellegata NS, Antoniono RJ, Redpath JL, Stanbridge EJ (1996)**: DNA damage and p53-mediated cell cycle arrest: A reevaluation. *Proc Natl Acad Sci USA*; 93: 15209–14.
133. **Perabo FG, Mattes RH, Wirger A, Steiner G, Schmidt D, Pegelow K, von Ruecker A, Muller SC (2001)**: Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo. *Int. Urol*; 6(4): 163-9.
134. **Pignataro L, Arisi E, Sambataro G, Corsi MM (2003)**: Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment. *J Surg Oncol*; 83(2):112-5.
135. **Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP (1996)**: Inhibition of fatty acid synthesis: a novel chemotherapeutic approach. *Proc Annu Meet Am Assoc Cancer Res*; 37: A2704.
136. **Pronk G, Ramer K, Amiri P, Williams L, (1996)**: Requirement of an ice-like protease for induction of apoptosis and ceramide generation by REAPER. *Science*; 271: 808-10.
137. **Rieux LF, Le DF, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP (1995)**: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. *Science*; 268: 1347-9.
138. **Rodel C, Grabenbauer GG, Rodel F (2000)**: Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: Possible predictors for response to radiochemotherapy and successful bladder preservation. *Int J Radiat Oncol Biol Phys*; 46: 1213–21.
139. **Rosin MP, Anwar WA, Ward AJ (1994)**: Inflammation, chromosomal instability and cancer: the schistosomiasis model. *Cancer Res*; 54: 929s–33s.
140. **Rozzo SJ, Eisenberg RA, Cohen PL (1994)**: Development of the T cell receptor repertoire in lpr mice. *Semin Immunol*; 6: 19-26.
141. **Salama M, El-Kholy G, Abd El-Haleem S, Elzamarany E, Abou Freikha M, Elwan N, El-Masry M, Al-Bacil A, Elhendy A (2003)**: Serum soluble Fas in patients with Schistosomal cor pulmonale. *Respiration*; 70(6): 574-8.

142. **Santana P, Pena A, Fuks Z, Kolesnick R, (1996):** Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. *Cell* 86, 189-99.
143. **Sarkis AS, Dalbagni G, Cordon-Cardo C (1993):** Nuclear overexpression of p53 protein in transitional cell carcinoma: a marker for disease progression. *J Natl Cancer Inst*; 85: 53.
144. **Schneider P, Holler N, Bodmer J, Hahne M, Frei K, Fontana A, Tschopp J (1998):** Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. *J Exp Med*; 187:1205-13.
145. **Sherr CJ (1996):** Cancer cell cycles. *Science*; 274:1672–7.
146. **Sherif M, Ibrahim A (1987):** The profile of cancer in Egypt, Arab World Printing House, Cairo.
147. **Shibutani yf, Schoenberg MP, Carpinello VL, Malloy TR (1992):** Human papilloma virus associated with bladder cancer. *Urology* 40: 15–7.
148. **Spruck CH, Ohneseit PF, Gonzales-Zulueta M (1994):** Two molecular pathways to transitional cell carcinoma of the bladder. *Cancer Res* 1994;54:784.
149. **Takahashi R, Hashimoto T, Xu HJ (1991):** The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. *Proc Natl Acad Sci USA* ; 88: 5257–61.
150. **Tanaka M, Suda T, Takahashi T, Nagata S, (1995):** Expression of the functional soluble form of human Fas ligand in activated lymphocytes. *EMBO J*; 14: 1129-35.
151. **Tepper C, Jayadev S, Liu B, Bielawska A, Wolff R, Yonehara S, Hannun Y, Seldin M (1995):** Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. *Proc Natl Acad Sci USA* 92: 8443-7.
152. **Tiniakos DG, Mellon K, Anderson JJ, Robinson KC, Neal NE, Horne CH (1994):** C-jun oncogene expression in transitional cell carcinoma of the urinary bladder. *Br J Urol*; 74: 757–61.
153. **Therrien JP, Drouin R, Baril C, Drobetsky EA (1999):** Human cells compromised for p53 function exhibit defective global and transcription-coupled nucleotide excision-repair, whereas cells compromised for pRb function are defective only in global repair. *PNAS*; 96: 15038–43.
154. **Thome M, Schneider P, Hofmann K, Fickenscher H, Meink E, Scaffidi C, Krammer P, Peter E, Tschopp J (1997):** Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. *Nature*; 386: 517-21.

155. **Thornberry NA, Lazebnik Y (1998):** Caspases: Enemies within. *Science*;281:1312–1316.
156. **Tsutsumi M, Tsai Y, Gonzalez ML (1998):** Early acquisition of homologous deletions of p16/p14 during squamous cell carcinogenesis and genetic in bladder cancer. *Oncogene*;17: 3021.
157. **UICC, (1978):**TNM classification of malignant tumors. In: UICC, 3rd ed., Geneva.
158. **Wang CY, Mayo MW, Baldwin AS (1996):** TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. *Science*; 274: 724.
159. **Warren W, Big PJ, El-Baz M, Ghoneim MA, Sttaton MR, Venitt S (1995):**, Mutations in the p53 in bilharzial bladder cancer: a study of 92 tumors from Egyptian patients and comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumors. *Carcinogenesis (Lond.)*; 16: 1181–9.
160. **Weintraub M, Khalid HM, Zekri AR (1995):** p53 mutations in Egyptian bladder cancer. *Int. J Oncol* ; 7 : 1269–74.
161. **Wolf BB, Green DR (1999):** Suicidal tendencies: Apoptotic cell death by caspase family proteinases. *J Biol Chem*; 274: 20049–52.
162. **Yanagisawa J, (1997):** The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. *J Biol Chem*; 272: 8539-45.
163. **Yonehara S, Ishii A, Yonehara M, (1989):** A cell killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of TNF. *J Exp Med*; 169: 1747-56.
164. **Younes M, Sussman J, True L (1990):** The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. *Cancer*; 66: 543.
165. **Young SW, Khalid KH, Farid Z, Mahmoud AH (1974):** Urinary tract lesions of *Schistosoma hematobium*. *Radiology*; 111: 81-4.
166. **Young RH, Wick MR, Mills SE (1988):** Sarcomatoid carcinoma of the urinary bladder: A clinicopathologic analysis of 12 cases and review of the literature. *Am J Clin Pathol* 1988;90:653.
167. **Yu H, Rohan T, (2000):** Role of the insulin-like growth factor family in cancer development and progression. *J. Natl, Cancer Inst.*; 92: 1472-89.
168. **Zaghloul MS (1996):** Distant metastases from bilharzial bladder cancer. *Cancer*;77:743.